How Much Does Sanofi Spend on Lobbying?

At $11.6M in disclosed federal lobbying, Sanofi ranks as a major spender — well above the typical filer. Outlays in this range generally reflect a sustained presence in Washington, with at least one full-time government affairs lead and a stable of outside lobbyists engaged on the organization's priority issues.

Sanofi's disclosed lobbying focuses on a narrow 4-issue footprint. A focused issue list usually means the organization concentrates its federal engagement on a small set of bills or rulemakings directly relevant to its core business.

The Senate Lobbying Disclosure Act requires anyone who contacts covered federal officials on behalf of a paying client — and crosses time and dollar thresholds — to register and file quarterly. Filings are publicly available through the Senate Office of Public Records, which is the original source for every dollar figure on this page. The same filings feed downstream research at OpenSecrets, where you can cross-reference individual lobbyists, bills tracked, and related campaign contributions.

4 of 8 lobbyists reported by Sanofi (50%) disclose prior federal government service — a high revolving-door share. The LDA cover sheet flags any "covered position" the lobbyist held in the executive branch, Congress, or a senior staff role within the past two years.

Among the named bench, lobbyists with disclosed prior federal service include Dorothy M. Phillips (Former Staff Director, House Energy & Commerce Committee); Patricia A. Hogan (Former Commissioner, FCC); Emily B. Parker (Former Staff Director, House Appropriations Committee). The covered-position field on LDA cover sheets captures executive-branch and senior congressional roles held within the prior two years.

Within the Pharmaceutical & Health Products sector, Sanofi ranks #0 of 33 tracked organizations by disclosed lobbying spend. The sector leader is Pharmaceutical Research & Manufacturers of America at $135.8M; the sector average is $16.9M. Sanofi's $11.6M sits 31% below the sector average.

Sanofi's LobbySpend Influence Score of 61/100 (grade B) reflects significant federal lobbying reach. The score blends disclosed total spend, issue breadth, and revolving-door connections — lobbyists with prior federal government service. A B-grade typically means the organization is well above average on at least two of those three signals, with sustained activity over multiple years rather than a one-off spike.

Across the 5-year window from 2020 to 2024, Sanofi's annual disclosed lobbying spend has held roughly steady — $2.5M at the start versus $2.3M at the most recent year-end. Year-to-year wobbles inside that range usually reflect timing of legislative cycles rather than a strategic shift.

Every dollar on this page comes from quarterly filings submitted under the Lobbying Disclosure Act and published by the Senate Office of Public Records. We pull those filings via the lda.senate.gov public API, deduplicate amendments, and aggregate by registrant or client across the years shown. The "amount" for each filing is the larger of reported income (for lobbying firms) or reported expenses (for in-house programs), which is the standard convention used by both the Senate's own dashboards and outside researchers including OpenSecrets.

The LobbySpend Influence Score is a composite indicator: 40% disclosed total spend, 30% number of distinct general issue areas lobbied on, and 30% share of named lobbyists with prior federal government service. The score is descriptive — it summarizes what was disclosed — and should not be read as a measure of effectiveness, ethics, or political outcomes. Read the full methodology for the exact formulas, caveats, and known limitations of LDA disclosures.